期刊
BIOLOGICAL PSYCHIATRY
卷 57, 期 4, 页码 430-432出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2004.11.023
关键词
antidepressant; bipolar disorder; depression; glutamatergic; riluzole
Background: Preclinical and clinical evidence indicate that the glutamatergic system might play a role in the pathophysiology of mood disorders. This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar depression. Methods: This was an 8-week add-on study of riluzole in combination with lithium in acutely depressed bipolar patients aged 18 years and older. After open treatment with lithium for a minimum period of 4 weeks, subjects who continued to have a Montgomery-Asberg Depression Rating Scale (MADRS) score of greater than or equal to20 received riluzole (50-200 mg/day) for 8 weeks. Results. Fourteen bipolar depressed patients entered the study. The linear mixed models for total MADRS score showed a significant treatment effect. No switch into hypomania or mania was observed. Overall, riluzole was well tolerated. Conclusions. Although preliminary, these results suggest that riluzole might indeed have antidepressant efficacy in subjects with bipolar depression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据